Spellman v. Commissioner

The landscape of research and development (R&D) taxation in the United States is defined by a sophisticated interplay between legislative incentives designed to spur innovation and judicial doctrines intended to curb the proliferation of passive tax shelters. At the heart of this legal architecture lies Section 174 of the Internal Revenue Code (IRC), a provision that has historically offered taxpayers a choice between the immediate expensing of research and experimental costs or their capitalization and amortization. However, the availability of these benefits is contingent upon the taxpayer satisfying the "trade or business" requirement, a standard that has evolved significantly since its inception in 1954. The 1988 decision by the United States Court of Appeals for the Seventh Circuit in Spellman v. Commissioner [845 F.2d 148] serves as a seminal moment in this evolution, establishing the "realistic prospect" test as the definitive standard for determining whether a taxpayer’s research activities possess the necessary operational nexus to a trade or business. As the tax regime transitions into the era of the One Big Beautiful Bill Act (OBBBA) of 2025, the principles articulated in Spellman continue to dictate the eligibility of startups, partnerships, and established corporations for billions of dollars in R&D incentives.

The Statutory Context and the Genesis of Section 174

To appreciate the gravity of the Spellman decision, one must first examine the legislative intent behind Section 174. Prior to 1954, the tax treatment of R&D costs was highly uncertain. Most research expenditures were required to be capitalized, meaning they could only be recovered over the life of a resulting patent or upon the total failure and abandonment of the project. This regime placed a significant financial burden on small and emerging companies that lacked the capital reserves of established industrial giants with dedicated research departments. Congress enacted Section 174 to provide a level playing field, specifically intending to encourage smaller firms and startups to invest in innovation by allowing them to deduct research costs immediately against other income.

The language of Section 174(a)(1) specifies that a taxpayer may treat research or experimental expenditures "paid or incurred by him during the taxable year in connection with his trade or business as expenses which are not chargeable to capital account". The phrase "in connection with" is critically distinct from the "carrying on" language found in Section 162, which governs ordinary business expenses. Section 162 generally requires that a taxpayer be actively engaged in an existing business—meaning they must be currently selling goods or services—before expenses can be deducted. In contrast, the Supreme Court’s 1974 ruling in Snow v. Commissioner clarified that Section 174’s "in connection with" language was intended to be broader and more inclusive of up-and-coming enterprises that had not yet reached the stage of commercial production.

While Snow resolved the temporal question—affirming that research itself could satisfy the "trade or business" requirement before a product was sold—it left open the operational question. It did not define the degree of involvement or the nature of the taxpayer's rights required to distinguish a legitimate business venture from a passive investment. This ambiguity led to the rise of R&D tax shelters in the late 1970s and 1980s, where limited partnerships were formed for the primary purpose of generating paper losses to offset the income of wealthy investors. It was in this environment that the Spellman case emerged.

Analysis of Spellman v. Commissioner: Facts and Findings

The Spellman litigation involved a taxpayer who was a limited partner in a partnership that, in turn, held an interest in a second partnership called Sci-Med. The business arrangement was structured to fund the development of a "Fast Clean System," a new cement-related technology, through a research and development agreement with Serv-Tech, a third-party corporation.

The Contractual Framework

The core of the dispute lay in the specific rights and obligations outlined in the agreements between the partnership and Serv-Tech. Under the research and development agreement, the partnership paid Serv-Tech to conduct the actual R&D work. While the partnership retained legal title to the resulting technology during the development phase, the surrounding agreements effectively stripped the partnership of any practical ability to manufacture or market the product themselves.

Specifically, the partnership granted Serv-Tech a series of exclusive options. Serv-Tech held an option to acquire an exclusive worldwide license to market the cement technology for a relatively nominal fee. Furthermore, Serv-Tech held a stock option, exercisable over a specific period, that allowed it to issue its own publicly traded stock in exchange for the limited partners' interests in the partnership. The private offering memorandum issued to investors explicitly stated that Serv-Tech, rather than the partnership, was expected to "acquire... [the technology], once developed, instead of the Partnership retaining it for use in its own trade or business".

The Seventh Circuit's Reasoning

Writing for the court, Judge Richard Posner focused on the economic reality of the transaction rather than its legal form. The court noted that the partnership had no employees, no office, and no specialized technical expertise. Its only function was to provide capital. Posner famously observed that the partnership’s retention of bare legal title to the technology did not put it in the business of manufacturing or marketing that technology any more than "foreclosing on a real estate mortgage would make a bank a real estate company".

The court established that to qualify for a Section 174 deduction, there must be a "realistic prospect" that the taxpayer would develop and exploit the technology in its own business, rather than merely acting as a passive financier for another entity's business. Because the contractual options essentially guaranteed that the technology would be commercialized by Serv-Tech if it were successful, the partnership's interest was characterized as that of a lender or an investor, not a participant in a trade or business.

The "Rational Actor" Analysis

A crucial insight from Spellman is the court's use of a "rational actor" standard. The court argued that it would be irrational for the partnership to enter the business of manufacturing and marketing the Fast Clean System themselves when they had already granted the counterparty the right to take over the technology for a fixed, low cost. If the research were successful, the developer would exercise its option; if it failed, there would be no business for the partnership to enter. Thus, in no realistic scenario would the partnership actually "carry on" the business.

The Progeny of Spellman and the Refining of the Test

In the years following the Spellman decision, other appellate circuits adopted and refined the realistic prospect test, creating a robust body of case law that governs Section 174 deductions for partnerships and startups.

Kantor v. Commissioner and the Ability to Commercialize

The Ninth Circuit in Kantor v. Commissioner [998 F.2d 1514] applied the Spellman logic to a partnership that funded the development of software designed to run on IBM computers. Like the Spellman partnership, the Kantor group contracted with a research firm and granted that firm a low-cost option ($5,000) for an exclusive license to market the software. The court found that the partnership lacked both the objective intent and the capability to enter the business. The partnership’s private placement memorandum had admitted that it lacked the capital necessary to market the software if the developer declined to do so.

LDL Research and the "Mere Possibility" Standard

The Tenth Circuit provided a significant expansion of the doctrine in LDL Research Development II Ltd v. Commissioner [124 F.3d 1338]. In this case, a Utah partnership funded research into electronic acoustic testing equipment. The court emphasized that a taxpayer must show more than a "mere possibility" of entering the business. Even though the partnership retained legal ownership and the developer’s marketing options were non-exclusive for a time, the court noted that the general partners lacked any experience in the industry and had no concrete plans to build a manufacturing or marketing infrastructure.

The Nexus Between Section 174 and the Section 41 Research Credit

While Spellman and its progeny were primarily concerned with the deductibility of research expenses under Section 174, their implications extend directly to the Section 41 Credit for Increasing Research Activities. This is because Section 41(d)(1)(A) defines "qualified research" as research "with respect to which expenditures may be treated as expenses under section 174". Consequently, if a taxpayer fails the realistic prospect test for Section 174, they are per se ineligible for the R&D tax credit.

The "Carrying On" vs. "In Connection With" Distinction

The Section 41 credit is actually more restrictive than the Section 174 deduction in its trade or business requirement. While Section 174 uses the "in connection with" standard (allowing for startups as per Snow), Section 41(b)(1) requires that qualified research expenses (QREs) be "paid or incurred by the taxpayer in carrying on any trade or business of the taxpayer".

This distinction creates a "startup hurdle." A pre-revenue company can deduct R&D costs under Section 174 (assuming it has a realistic prospect of business) but may not be able to claim the Section 41 credit until it actually begins commercial activity. However, there are specific exceptions for "in-house research" where the taxpayer intends to use the results in a future business, provided the Spellman criteria are met.

The Funded Research Exclusion and Substantial Rights

A major area of modern litigation involves "funded research." Under Section 41(d)(4)(H), a taxpayer cannot claim a credit for research to the extent it is funded by another person. The regulations interpret "funded" through a two-prong test:

• Economic Risk: Does the taxpayer bear the financial risk of failure?
• Substantial Rights: Does the taxpayer retain the right to exploit the research results?

The realistic prospect test from Spellman is the ideological ancestor of the "substantial rights" analysis. In Lockheed Martin Corp. v. United States, the Federal Circuit held that "substantial rights" exist if the taxpayer can use the research results in its own business without paying for the privilege. If a contract—similar to the ones in Spellman—conveys all rights to a third-party client or grantor, the researcher is considered "funded" and cannot claim the credit.

The 2024-2025 Jurisprudential Shift: Phoenix Design and Smith

Two very recent cases highlight how the principles of Spellman are being applied in the current regulatory environment.

Phoenix Design Group and the Process of Experimentation

In December 2024, the Tax Court issued a pivotal ruling in Phoenix Design Group, Inc. v. Commissioner. The court disallowed R&D credits for an engineering firm, finding that it failed to demonstrate a "systematic process of experimentation". Drawing on the Spellman legacy of scrutinizing the operational reality, the court found that the firm’s "six-stage design process" was merely a linear path to a known solution, rather than an iterative process intended to resolve technical uncertainty. The court also upheld a 20% accuracy-related penalty, sending a clear message that contemporaneous, activity-level documentation is non-negotiable.

Smith and System Technologies: Victories for Contractors

Conversely, in early 2025, the Tax Court sided with taxpayers in Smith v. Commissioner and System Technologies Inc. v. Commissioner. These cases dealt with architectural and engineering firms performing research under contract. The IRS argued that the research was "funded" because the contracts did not explicitly state that the taxpayer retained all intellectual property. However, the court ruled that because the taxpayers were only paid upon reaching certain "milestones" and retained the right to use the underlying technical information in their future work, they possessed both the economic risk and the substantial rights required for the credit. These rulings suggest a softening of the Spellman "exclusivity" requirement, recognizing that "shared rights" can still support a trade or business nexus.

The One Big Beautiful Bill Act (OBBBA) of 2025

The most transformative development in R&D taxation since the enactment of Section 174 is the passage of the One Big Beautiful Bill Act (OBBBA), signed into law by President Trump on July 4, 2025. This legislation represents a complete reversal of the controversial R&D capitalization rules introduced by the 2017 Tax Cuts and Jobs Act (TCJA).

The Restoration of Section 174A

Under the TCJA, beginning in 2022, companies were required to capitalize domestic R&D costs and amortize them over five years, which created severe cash-flow issues for capital-intensive industries. The OBBBA restores the status quo ante for domestic research through the creation of a new Section 174A, which permanently allows for the full expensing of domestic research costs in the year incurred.

Retroactive Relief and the $31 Million Threshold

One of the most striking provisions of the OBBBA is the retroactive relief granted to "eligible small businesses"—defined as those with average annual gross receipts of $31 million or less for the preceding three years. These firms can amend their 2022, 2023, and 2024 tax returns to immediately expense their R&D costs and claim refunds for the taxes paid under the TCJA's capitalization rules.

For larger corporations that do not meet the $31 million threshold, the OBBBA provides a "turbo depreciation" option. These companies can elect to accelerate the deduction of their remaining unamortized domestic R&D costs from 2022-2024 over a one- or two-year period beginning in 2025.

The Bifurcated Research Economy

The OBBBA maintains the TCJA's requirement that foreign research expenditures—those conducted outside the United States—must be capitalized and amortized over 15 years. This creates a powerful tax incentive for companies to repatriate their research activities. The "realistic prospect" test will now be applied in a bifurcated context: a company must not only show it is in a trade or business but must precisely track where its R&D activities are occurring to ensure they qualify for the Section 174A immediate deduction rather than the Section 174 15-year amortization.

Implications for Future R&D Tax Credit Applications

The synergy between the Spellman doctrine and the new OBBBA framework has several profound implications for the future of R&D tax credit applications in the United States.

The "SRE Product Right" Requirement

Recent IRS guidance (Notice 2023-63 and Notice 2024-12) has formalized the "realistic prospect" concept through the introduction of the "Specified Research and Experimentation (SRE) Product Right". To recognize an expenditure under Section 174 (and thus qualify for the Section 41 credit), a research provider must have the right to use the resulting product in its own trade or business or exploit it through sale, lease, or license without needing separate authorization or payment to a third party. This is a direct regulatory manifestation of the Spellman holding: if you cannot commercialize the result independently, you are not in the business.

Substantiation and the Burden of Proof

The IRS has designated R&D credit refund claims as a Tier I issue, indicating the highest level of audit scrutiny. The Phoenix Design Group and Kyocera cases demonstrate that "reconstructions" and "estimates"—often called the Cohan rule—are no longer sufficient to carry a taxpayer's burden of proof.

Taxpayers must now provide "activity-level" documentation that links specific employee hours and supply costs to "business components" (products, processes, software, or techniques). The failure to provide this documentation not only leads to the disallowance of the credit but also the imposition of 20% accuracy-related penalties under Section 6662.

The Role of Software Development

Under both Section 174A and Section 41, software development is statutorily included as a qualified activity. However, the "realistic prospect" test is particularly challenging for software startups that may be developing a platform with the sole intent of being acquired by a larger tech firm (the "exit strategy"). To satisfy Spellman, these startups must demonstrate that their business model includes a viable path to independent commercialization—such as a Software-as-a-Service (SaaS) model—even if their primary hope is acquisition.

Strategy for Small Business Retroactive Claims

Small businesses seeking to utilize the OBBBA’s retroactive relief must act quickly. The deadline for filing amended returns to claim the immediate expensing of 2022-2024 R&D costs is generally July 4, 2026. These claims must be "bulletproof" before submission, as the IRS uses the new "Classifier review system" to deny refund claims that lack a clear breakdown of business components and a strong narrative of experimentation before they even reach an examiner.

The Future of Section 174 and the Realistic Prospect Doctrine

As the United States enters a period of renewed investment in domestic innovation, the trade or business requirement of Section 174 stands as the primary filter for government R&D subsidies. The Spellman decision established that the operational nexus of a business must be real, active, and economically rational. In the post-OBBBA world, where domestic R&D is highly favored over foreign research, the ability to prove a "realistic prospect" of exploitation will be the difference between a successful tax position and a costly audit failure.

The evolution of the law—from the temporal leniency of Snow to the operational rigor of Spellman and the administrative strictness of Phoenix Design—reflects a maturing tax system. The government is willing to provide massive incentives for innovation, but only to those who can demonstrate they are truly engaged in the "experimental or laboratory sense" and have the capacity to bring their innovations to the domestic market. For taxpayers and their advisors, the path forward requires a deep understanding of contractual rights, a commitment to contemporaneous record-keeping, and a strategic focus on the operational realities of their research endeavors.

The Spellman doctrine, far from being a relic of the 1980s, has become the foundational stone of modern R&D tax planning. It serves as a reminder that in the eyes of the law, the "business of innovation" is not merely the act of discovery, but the creation of a tangible mechanism for economic exploitation within the taxpayer’s own enterprise.